Volume | 174,768 |
|
|||||
News | - | ||||||
Day High | 0.52989 | Low High |
|||||
Day Low | 0.49 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Aligos Therapeutics Inc | ALGS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.50 | 0.49 | 0.52989 | 0.50 | 0.5081 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
701 | 174,768 | $ 0.5014072 | $ 87,630 | - | 0.49 - 1.20 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:46:28 | formt | 300 | $ 0.502 | USD |
Aligos Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
37.83M | 75.67M | - | 15.53M | -87.68M | -1.16 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Aligos Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALGS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.5649 | 0.6029 | 0.49 | 0.526583 | 180,706 | -0.0629 | -11.13% |
1 Month | 0.66 | 0.7545 | 0.49 | 0.60879 | 275,700 | -0.158 | -23.94% |
3 Months | 0.923 | 1.10 | 0.49 | 0.8032293 | 268,321 | -0.421 | -45.61% |
6 Months | 0.57 | 1.20 | 0.49 | 0.7967596 | 338,281 | -0.068 | -11.93% |
1 Year | 1.12 | 1.20 | 0.49 | 0.7867337 | 237,239 | -0.618 | -55.18% |
3 Years | 32.68 | 33.58 | 0.49 | 4.05 | 262,621 | -32.18 | -98.46% |
5 Years | 14.74 | 37.5099 | 0.49 | 5.86 | 237,890 | -14.24 | -96.59% |
Aligos Therapeutics Description
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others. |